Arena Pharma (ARNA) Tops Q4 EPS by 24c, Beats on Revenues

Note: EPS may not be comparable

Arena Pharma (NASDAQ: ARNA) reported Q4 EPS of ($0.35), $0.24 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $7.57 million.

Financial Update

Fourth Quarter 2017 Financial Results

• Revenues totaled $15.4 million, consisting of $14.2 million in collaboration revenue, and $1.2 million in royalty revenue from Eisai. Included in the collaboration revenue is the $12.0 million upfront fee Arena received from Everest in connection with the development and commercialization partnership.
• Research and development expenses totaled $20.7 million
• General and administrative expenses totaled $8.3 million
• Net loss attributable to stockholders of Arena was $13.7 million, or $0.35 per share

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c